MEDIA & PRESS UPDATES

Medilabo RFP today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for ML 1707, a potential therapy for the treatment of Frontotemporal Dementia (FTD). (March 9, 2023)

This important designation is a milestone in the development of ML 1707 and highlights the need for potential new treatment options for patients with FTD.

Medilabo RFP's finding of rifampicin attenuates C9orf72-linked dementia was featured in a News medical (May 23, 2022)

Antibiotic rifampicin attenuates C9orf72-linked dementia in genetically modified mice

Excellent efficacy of Medilabo RFP's nasal rifampicin and resveratrol combination in neurodegenerative dementia was introduced in Science Daily (Dec 19, 2021)

Stopping dementia at the nose with combination of rifampicin and resveratrol

Medilabo RFP Awarded 2021 "Industry-Academia-Public Forest" promotion project for business facilitation (Oct 1, 2020)

Development of dementia preventive drug with increased development success rate